Thera-SAbDab

IANALUMAB

>   Structural Summary
TherapeuticIanalumab
TargetTNFRSF13C
Heavy ChainQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSS
Light ChainDIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '22)Phase-II/III
Estimated Status (Aug '22)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedH. Lee Moffitt Cancer Center and Research Institute, MorphoSys, Novartis
Conditions Approvedna
Conditions ActiveAutoimmune hepatitis, Idiopathic pulmonary fibrosis, Multiple sclerosis, Pemphigus vulgaris, Rheumatoid arthritis, Sjogren's syndrome, Systemic lupus erythematosus, Chronic lymphocytic leukaemia
Conditions Discontinuedna
Notes(Feb '22) Residue 108 changed from Q to D according to amendment in RL83. (June '22) Corrected CDRL1/CDRL3 sequences.

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy